GlassScriptPhysician profile
Ali Wakil
NPI 1730609637
$7,503.04
in general payments reported to CMS, 2019-2025
23 companies · $3,958 in 2025
The $3,958 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $96.07 · 2023: $1,502 · 2024: $1,946 · 2025: $3,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,690 · Travel and Lodging: $603 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,690.39 |
| Travel and Lodging | $602.77 |
| Education | $113.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,478.48 | 2023-2025 | Mavyret, Rinvoq, Skyrizi |
| Gilead Sciences, INC. | $1,600.62 | 2022-2025 | Epclusa, Livdelzi, Vemlidy |
| Madrigal Pharmaceuticals | $702.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $672.93 | 2025 | Tremfya |
| Olympus Corporation of The Americas | $637.90 | 2025 | Single Use Biliary Balloon Dilator, Hanarostent Esophagus Tts(Ccc) |
| Phathom Pharmaceuticals, INC. | $398.36 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $161.74 | 2024-2025 | Entyvio, Eohilia |
| Novo Nordisk INC | $140.17 | 2023-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $125.18 | 2024 | Zeposia |
| Celltrion USA INC. | $104.88 | 2024-2025 | Vegzelma, Zymfentra |
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Celgene Corporation | $67.75 | 2024 | Zeposia |
| Medtronic, INC. | $65.43 | 2024 | Nexpowder |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.10 | 2024 | Cyltezo |
| Lilly USA, LLC | $34.01 | 2025 | Omvoh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $31.12 | 2025 | Heplisav-B |
| Ardelyx, INC. | $30.99 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $26.40 | 2024 | Suflave, Sutab |
| Micro-Tech Endoscopy USA, INC. | $25.29 | 2024 | Eyemax, Lockado |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.89 | 2025 | Xifaxan |
| Capsovision, INC. | $21.54 | 2023 | Capsocam Plus |
| Orphalan INC | $21.08 | 2025 | Cuvrior |
| Avanos Medical | $13.29 | 2023 | Initial Placement Kits |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Wakil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.